Search hospitals > West Virginia > Charleston

West Virginia University Charleston Division

Claim this profile
Charleston, West Virginia 25304
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Adenocarcinoma
Conducts research for Breast Cancer
172 reported clinical trials
5 medical researchers
Photo of West Virginia University Charleston Division in CharlestonPhoto of West Virginia University Charleston Division in Charleston

Summary

West Virginia University Charleston Division is a medical facility located in Charleston, West Virginia. This center is recognized for care of Cancer, Leukemia, Tumors, Adenocarcinoma, Breast Cancer and other specialties. West Virginia University Charleston Division is involved with conducting 172 clinical trials across 379 conditions. There are 5 research doctors associated with this hospital, such as Steven J. Jubelirer, Ahmed A. Khalid, Ashley E. Meyer, and Mohamad H. Badawi.

Area of expertise

1Cancer
Global Leader
West Virginia University Charleston Division has run 57 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Leukemia
Global Leader
West Virginia University Charleston Division has run 23 trials for Leukemia. Some of their research focus areas include:
CD5 positive
Stage II
Stage III

Top PIs

Clinical Trials running at West Virginia University Charleston Division

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Prostate Cancer
Diffuse Large B-Cell Lymphoma
Squamous Cell Carcinoma
Rhabdomyosarcoma
Follicular Lymphoma
Ovarian Cancer
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This study is evaluating whether a combination of two drugs may help prevent breast cancer from coming back.
Recruiting1 award Phase 313 criteria
Image of trial facility.

Chemotherapy Reduction After Surgery

for Breast Cancer

This study is evaluating whether a combination of drugs may help treat breast cancer.
Recruiting1 award Phase 227 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at West Virginia University Charleston Division?
West Virginia University Charleston Division is a medical facility located in Charleston, West Virginia. This center is recognized for care of Cancer, Leukemia, Tumors, Adenocarcinoma, Breast Cancer and other specialties. West Virginia University Charleston Division is involved with conducting 172 clinical trials across 379 conditions. There are 5 research doctors associated with this hospital, such as Steven J. Jubelirer, Ahmed A. Khalid, Ashley E. Meyer, and Mohamad H. Badawi.